Accordingly, PSMA expression in HCC neovasculature is fundamental for PSMA-targeting radiopharmaceuticals for imaging and therapy (18), which will facilitate new diagnosis and treatment modalities for HCC. This evidence concerns the gene FOLH1 and hepatocellular carcinoma.